stage disease. In addition, the AR gene is amplified and/or overexpressed in about 30% in the hormone-therapy refractory tumors, and it has been proposed this could sensitize the receptor for the residual androgen concentrations and antiandrogens present beneath hormonal therapies. Additionally, quite a few AR mutations, resulting in enhanced activity or broadened ligand-specificity to alternative


Who Upvoted this Story